Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Prelude Therapeutics Q3 EPS $(0.45) Beats $(0.58) Estimate

Author: Benzinga Newsdesk | November 01, 2023 05:50pm
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.58) by 22.41 percent. This is a 28.57 percent increase over losses of $(0.63) per share from the same period last year.

Posted In: PRLD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist